In vitro systems for prediction of rates of drug clearance and drug interactions

Editorial

F J Gonzalez. Anesthesiology. 1992 Sep.

. 1992 Sep;77(3):413-5.

doi: 10.1097/00000542-199209000-00001.

No abstract available

Comment on

Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance.
Yun CH, Wood M, Wood AJ, Guengerich FP. Yun CH, et al. Anesthesiology. 1992 Sep;77(3):467-74. doi: 10.1097/00000542-199209000-00011. Anesthesiology. 1992. PMID: 1519785 Review.

In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach.
Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, Tremaine LM. Obach RS, et al. Clin Pharmacol Ther. 2005 Dec;78(6):582-92. doi: 10.1016/j.clpt.2005.09.004. Clin Pharmacol Ther. 2005. PMID: 16338274 Review. No abstract available.
Drug interactions with spiramycin: lack of influence on antipyrine pharmacokinetics.
Descotes J, Evreux JC. Descotes J, et al. Chemioterapia. 1987 Jun;6(2 Suppl):337-8. Chemioterapia. 1987. PMID: 3509440 No abstract available.
Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.
Bertz RJ, Granneman GR. Bertz RJ, et al. Clin Pharmacokinet. 1997 Mar;32(3):210-58. doi: 10.2165/00003088-199732030-00004. Clin Pharmacokinet. 1997. PMID: 9084960 Review.
Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.
Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Ito K, et al. Pharmacol Rev. 1998 Sep;50(3):387-412. Pharmacol Rev. 1998. PMID: 9755288 Review. No abstract available.
The impact of cytochrome P450 allosterism on pharmacokinetics and drug-drug interactions.
Shou M. Shou M. Drug Discov Today. 2004 Aug 1;9(15):636-7. doi: 10.1016/S1359-6446(04)03132-0. Drug Discov Today. 2004. PMID: 15279845 No abstract available.

Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.
von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. von Moltke LL, et al. Br J Clin Pharmacol. 1994 Jul;38(1):23-31. doi: 10.1111/j.1365-2125.1994.tb04317.x. Br J Clin Pharmacol. 1994. PMID: 7946933 Free PMC article.